Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist.
Compton, B.J., Farrand, K.J., Tang, C.W., Osmond, T.L., Speir, M., Authier-Hall, A., Wang, J., Ferguson, P.M., Chan, S.T.S., Anderson, R.J., Cooney, T.R., Hayman, C.M., Williams, G.M., Brimble, M.A., Brooks, C.R., Yong, L.K., Metelitsa, L.S., Zajonc, D.M., Godfrey, D.I., Gasser, O., Weinkove, R., Painter, G.F., Hermans, I.F.(2019) Org Biomol Chem 17: 1225-1237
- PubMed: 30656346 
- DOI: 10.1039/c8ob02982b
- Primary Citation of Related Structures:  
5VCJ - PubMed Abstract: 
Activated NKT cells can stimulate antigen-presenting cells leading to enhanced peptide antigen-specific immunity. However, administration of potent NKT cell agonists like α-galactosylceramide (α-GalCer) can be associated with release of high levels o ...